Sector News

Merck KGaA to buy Sigma-Aldrich for $17 billion

September 22, 2014
Life sciences
(Reuters) – German drugs and chemicals maker Merck KGaA (MRCG.DE) said on Monday it agreed to acquire Sigma-Aldrich (SIAL.O) for $17 billion (10.41 billion pounds) in cash to boost its life science business.
 
The deal, approved by Sigma-Aldrich’s management, will see Merck acquire all shares for $140 apiece in cash.
 
That represents a 37 percent premium over the latest closing price of $102.37 on Sept. 19 and a 36 percent premium to the one-month average closing price, according to Merck.
 
(Reporting by Ludwig Burger; Editing by Georgina Prodhan)

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend